Intrapericardial delivery enhances cardiac effects of sotalol and atenolol

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 1, 2004, Pages 50-56

  Van Brakel, Thomas J ^a,c   Hermans, J J Rob ^b   Janssen, Ben J ^b   Van Essen, Helma ^b   Botterhuis, Nicole ^b   Smits, Jos F M ^b   Maessen, Jos G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adrenergic blockade; Antiarrhythmic; Antitachycardiac; Intrapericardial; Local drug delivery

Indexed keywords

ATENOLOL; DOBUTAMINE; NITROPRUSSIDE SODIUM; SOTALOL;

ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG TISSUE LEVEL; HEART FUNCTION; HEART LEFT VENTRICLE; HEART VENTRICLE COMPLIANCE; HEART VENTRICLE CONTRACTILITY; INTRAPERICARDIAL DRUG ADMINISTRATION; MALE; NONHUMAN; PERICARDIUM; PRIORITY JOURNAL; RAT; TACHYCARDIA;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATENOLOL; BODY WEIGHT; DRUG DELIVERY SYSTEMS; INFUSIONS, INTRALESIONAL; INFUSIONS, INTRAVENOUS; MALE; MYOCARDIAL CONTRACTION; PERICARDIUM; RATS; RATS, WISTAR; SOTALOL;

EID: 3042698137     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200407000-00007     Document Type: Article

References (34)

1. Zipes DP. Targeted drug therapy. Circulation. 1990;81:1139-1141.
2. Sellke FW, Simons M. Angiogenesis in cardiovascular disease: current status and therapeutic potential. Drugs. 1999;58:391-396.
3. Spodick DH. Intrapericardial therapeutics and diagnostics. Am J Cardiol. 2000;85:1012-1014.
4. Members of the Sicilian Gambit. New approaches to antiarrhythmic therapy part I: emerging therapeutic applications of the cell biology of cardiac arrhythmias. Circulation. 2001;104:2865-2873.
5. Members of the Sicilian Gambit. New approaches to antiarrhythmic therapy part II: emerging therapeutic applications of the cell biology of cardiac arrhythmias. Circulation. 2001;104:2990-2994.
6. Spodick DH. Macrophysiology, microphysiology and anatomy of the pericardium: a synopsis. Am Heart J. 1992;124:1046-1051.
7. Laham RJ, Rezaee M, Post M, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther. 2000;292:795-802.
8. Lazarous DF, Shou M, Stiber JA, et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res. 1997;36:78-85.
9. Uchida Y, Yanagisawa-Miwa A, Nakamura F, et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J. 1995;130:1182-1188.
10. Baek SH, Hrbie JA, Keefer LK, et al. Augmentation of intrapericardial nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation. 2002;105:2779-2784.
11. Waxman S, Moreno R, Rowe KA, et al. Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: a novel approach for local cardiac drug delivery. J Am Coll Cardiol. 1999;33:2073-2077.
12. Willerson JT, Igo SR, Yao SK, et al. Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries. Texas Heart Inst J. 1996;23:1-8.
13. Ujhelyi MR, Hadsall KZ, Euler DE, et al. Intrapericardial therapeutics: a pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery. J Cardiovasc Electrophysiol. 2002;13:605-611.
14. Moreno R, Waxman S, Rowe K, et al. Intrapericardial beta-adrenergic blockade with esmolol exerts a potent antitachycardic effect without depressing contractility. J Cardiovasc Pharmacol. 2000;36:722-727.
15. Fei L, Baron AD, Henry DP, et al. Intrapericardial delivery of L-arginine reduces the increased severity of ventricular arrhythmias during sympathetic stimulation in dogs with acute coronary occlusion: nitric oxide modulates sympathetic effects on ventricular electrophysiological properties. Circulation. 1997;96:4044-4049.
16. Geller L, Merkely B, Szokodi I, et al. Electrophysiological effects of intrapericardial infusion of endothelin-1. Pacing Clin Electrophysiol. 1998;21:151-156.
17. Ayers GM, Rho TH, Ben-David J, et al. Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. J Cardiovasc Electrophysiol. 1996;7:713-721.
18. Darsinos JT, Karli JN, Samouilidou EC, et al. Distribution of amiodarone in heart tissues following intrapericardial administration. Int J Clin Pharmacol Ther. 1999;37:301-306.
19. Labhasetwar V, Levy RJ. Novel delivery of antiarrhythmic agents. Clin Pharmacokinet. 1995;29:1-5.
20. Labhasetwar V, Underwood T, Gallagher M, et al. Sotalol controlled-release systems for arrhythmias: in vitro characterization, in vivo drug disposition, and electrophysiologic effects. J Pharm Sci. 1994;83:156-164.
21. Hermans JJR, van Essen H, Struijker-Boudier, et al. Pharmacokinetic advantage of intrapericardially applied supstances in the rat. J Pharmacol Exp Ther. 2002;301:672-678.
22. Kleinjans JC, Smits JFM, van Essen H, et al. Hemodynamic characterization of hypertension induced by chronic intrarenal or intravenous infusion of norepinephrine in conscious rats. Hypertension. 1984;6:689-699.
23. Lemmer B, Ohm T, Winkler H. Determination of beta-adrenoceptor blocking drug sotalol in plasma and tissue of the rat by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 1994;309:187-192.
24. Läer S, Neumann J, Scholz H, et al. Determination of sotalol in human cardiac tissue by high-performance liquid chromatography. J Chromatogr. 1996;681:291-298.
25. Smits JFM, Coleman TG, Smith TL, et al. Effect of propranolol in conscious spontaneously hypertensive rats: central hemodynamics, plasma volume and renal function during β-blockade with propranolol. J Cardiovasc Pharmacol. 1882;4:904-914.
26. Janssen BJ, Oosting J, Slaaf DW, et al. Hemodynamic basis of oscillations in systemic arterial pressure in conscious rats. Am J Physiol. 1995;269:H62-H71.
27. Lew MJ, Ludbrook J, Pavia LM, et al. Selective manipulation of neurohumoral control of the cardiac pacemaker by drugs given intrapericardially. J Pharmacol Methods. 1987;17:137-148.
28. Abrahamsson C, Palmer M, Ljung B, et al. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc Res. 1994;28:337-344.
29. k blocking drug UK68;798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol. 1990;16:401-410.
30. Hou D, March KL. A novel percutaneous technique for accessing the normal pericardium: a single-center successful experience of 53 porcine procedures. J Invasive Cardiol. 2003;15:13-17.
31. Spodick DH. Intrapericardial therapy and diagnosis. Curr Cardiol Rep. 2002;4:22-25.
32. Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens. 2001;14:231S-236S.
33. Reimold SC. Avoiding drug problems. The safety of drugs for supraventricular tachycardia. Eur Heart J. 1997;18:Cc40-Cc4.
34. MacNeil DJ. The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. Am J Cardiol. 1997;80:90G-98G.